MedTrace Logo

Botulinum Toxins Intralesional Injection for Scar Pain

NCT03982862 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-06-17

No results posted yet for this study

Summary

Botulinum toxins has been approved by the FDA to treat chronic migraine. Botox had been shown to inhibiting the release of inflammatory mediators and peripheral neurotransmitters from sensory nerve to treat neuropathic pain. In the clinical practice, botox indeed effect in scar pain. However, investigators need well controlled study to prove this finding and assess the improvement of scar appearance.

Conditions

  • Scar Keloid
  • Hypertrophic Scar

Interventions

DRUG

Triamcinolone

Triamcinolone 4mg diluted to 0.1 ml

DRUG

Lidocaine

0.1ml 2% Xylocaine

DRUG

Botulinum toxin A

4U Botox® diluted to 0.1 ml

Sponsors & Collaborators

  • Kaohsiung Medical University

    lead OTHER

Principal Investigators

  • Shu Hung Huang, MD, PHD · Kaohsiung Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-30
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03982862 on ClinicalTrials.gov